We read with great interest the Review by Solange Peters and Alex Adjei (MET: a promising anticancer therapeutic target. Nat. Rev. Clin. Oncol. 9, 314-326; 2012) on targeting the MET pathway as an anti cancer target.
1 In this highquality paper, the authors focus on the current challenges and the most promising drug combi nations of conventional chemotherapy and tar geted agents.
1 Using the example of rilo tumumab, the authors briefly underscored the preclinical rationale of inhibiting the MET pathway in combination with radio therapy. 2 We would like to further highlight how MET is involved in radiation resistance and how targeting the hepatocyte growth factor (HGF)-MET activation loop shows promise for enhancing the anti tumour effects of radiotherapy.
Recently, De Bacco et al. 3 investigated this issue and demonstrated that ionizing radiation could induce the expression and activity of the MET oncogene. After irra diation, MET expression in breast cancer cell lines was increased up to fivefold, and this overexpression increased ligand independent MET phosphorylation and signal transduction, which protects cells from apoptosis.
3 Cells that survived irra diation also became increasingly invasive, an effect that was driven through acti vation of the ataxia telangiectasia mutated (ATM) and nuclear factor κB (NFκB) signalling pathways.
The role of the stroma in this process should be highlighted. The epithelialmesenchymal transition refers to the acquisition of a fibroblast phenotype as well as increased cellular migration and prolifer ation in response to irradiation. 4 This programme is partially controlled by HGF, which is produced by irradiated MET targeting: perspectives for the radiation oncologist
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fibroblasts. HGF is involved in ionizing radiationinduced cell invasion and in the frequent metastatic relapses observed in patients after radiotherapy.
3 These effects are counter balanced in vivo by treatment with MET inhibitors, which enhance the efficacy of radiotherapy, at least in a xenograft animal model.
3
The induction of the ATM pathway is consistent with other reports that suggest MET is involved in DNA repair after exposure to radiotherapy.
2,5 Indeed, MET inhibition has been shown to impair the formation of the RAD51-BRCA2 complex, which is involved in the homologous repair of doublestrand DNA breaks. 6 Additionally, MET expression correlates with increased hypoxia, which is the most powerful factor of resistance to ionizingradiation therapy. Pennacchietti et al. 7 have shown that hypoxia triggers transcription of the MET oncogene as well as amplifies HGF signal ling and synergizes with HGF to induce activation of the downstream MET pathway.
Finally, Peters and Adjei note that pre clinical data showing how MET inhibitors overcome resistance to EGFR inhibitors have not been recapitulated in patients.
1 To date, all available clinical data on radiotherapy combined with tyrosine kinase inhibitors that block EGFR have been disap pointing. In this setting, targeting MET could be particularly promising for enhan cing the effectiveness of radiotherapy alone or when combined with EGFR inhibitors. In fact, surviving cells become resistant to ionizing radiation therapy through enhanced MET signalling and activation of the downstream antiapoptotic PI3K/Akt pathway. 3, 8 Thus, dual inhibition of EGFR and MET could be promising for enhancing the efficacy of radiotherapy.
We are totally in agreement with Peters and Adjei that the use of bio markers is important for selecting candidates to receive MET inhibitors. 1 Tomorrow's rationally designed clinical trials should incorporate biomarkers of tumour response or of metastatic dissemination to optimize therapy with MET inhibitors in combination with radiotherapy.
